Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 8/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | PRSS12 | P56730 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1266714 | 0.96 | SMO (0.36) | SMOALDH1A1LMNARECQLSMN1; SMN2 | |
| SCHEMBL1266721 | 0.96 | SMO (0.36) | SMOALDH1A1LMNARECQLSMN1; SMN2 | |
| SCHEMBL1266549 | 0.93 | ALDH1A1 (0.35) | SMOALDH1A1LMNARECQLSMN1; SMN2 | |
| SCHEMBL1267323 | 0.90 | SMO (0.39) | SMOALDH1A1LMNARECQLSMN1; SMN2 | |
| SCHEMBL1267400 | 0.87 | HTR7 (0.37) | SMOALDH1A1LMNARECQLC5AR1 | |
| SCHEMBL1266507 | 0.87 | HTR7 (0.37) | SMOALDH1A1LMNARECQLC5AR1 | |
| SCHEMBL1266526 | 0.87 | ALDH1A1 (0.41) | ALDH1A1LMNARECQLSMN1; SMN2HTR2A | |
| SCHEMBL1266862 | 0.86 | ALDH1A1 (0.41) | ALDH1A1LMNARECQLSMN1; SMN2HTR2A | |
| SCHEMBL2955571 | 0.85 | ALDH1A1 (0.43) | ALDH1A1LMNARECQLSMN1; SMN2KDM4E | |
| SCHEMBL3836653 | 0.85 | ALDH1A1 (0.40) | ALDH1A1LMNARECQLSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034495-A1 | Method of Modulating Stress-Activated Protein Kinase System | INTERMUNE, INC. (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034495-A1 | Method of Modulating Stress-Activated Protein Kinase System | MAPKAPK2, MAP3K6, MAP3K2 | SMO 4427/4885ALDH1A1 4333/4885LMNA 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.